Faruqi & Faruqi Reminds Hims & Hers Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 25, 2025
If you purchased or acquired securities in Hims between April 29, 2025 and June 22, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
NEW YORK, July 15, 2025 /PRNewswire/ — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Hims & Hers Health, Inc. ('Hims' or the 'Company') (NYSE: HIMS) and reminds investors of the August 25, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) that Hims was engaged in the 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy® that put patient safety at risk;' (2) that, as a result, there was a substantial risk that the Company's collaboration with Novo Nordisk would be terminated; and (3) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
On June 23, 2025, Novo Nordisk announced that it was ending its partnership with Hims, stating that Hims 'has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk.' Novo Nordisk further stated 'the 'semaglutide' active pharmaceutical ingredients that are in the knock-off drugs sold by telehealth entities and compounding pharmacies' may contain 'unsafe and illicit foreign ingredients.'
On this news, Hims' stock price fell $22.24, or 34.6%, to close at $41.98 per share on June 23, 2025, thereby injuring investors.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding Hims' conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the Hims & Hers Health class action, go to www.faruqilaw.com/HIMS or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malaysian Reserve
12 hours ago
- Malaysian Reserve
CIBC Asset Management announces CIBC ETF cash distributions for July 2025
TORONTO, July 25, 2025 /CNW/ – CIBC (TSX: CM) (NYSE: CM) – CIBC Asset Management Inc. today announced the July 2025 cash distributions for CIBC ETFs and ETF Series of the CIBC Fixed Income Pools, which distribute monthly and quarterly. Unitholders of record on July 31, 2025, will receive cash distributions payable on August 6, 2025. Details of the final 'per unit' distribution amounts are as follows: CIBC ETF Ticker Symbols Exchange Cash Distribution Per Unit ($) CIBC Canadian Government Long-Term Bond ETF CALB TSX $0.040 CIBC USD Premium Cash Management ETF (USD)* CUSD.U TSX $0.20 CIBC Premium Cash Management ETF CCAD TSX $0.13 CIBC Active Investment Grade Corporate Bond ETF CACB TSX $0.074 CIBC Active Investment Grade Floating Rate Bond ETF CAFR TSX $0.056 CIBC Flexible Yield ETF (CAD-Hedged) CFLX TSX $0.077 CIBC Conservative Fixed Income Pool ETF CCNS TSX $0.062 CIBC Core Fixed Income Pool ETF CCRE TSX $0.063 CIBC Core Plus Fixed Income Pool CPLS TSX $0.075 CIBC Canadian Bond Index ETF CCBI TSX $0.048 CIBC Canadian Short Term Bond Index ETF CSBI TSX $0.050 CIBC Global Bond ex-Canada Index ETF (CAD-Hedged) CGBI TSX $0.041 CIBC Sustainable Canadian Core Plus Bond Fund CSCP CBOE $0.057 CIBC Qx Canadian Low Volatility Dividend ETF CQLC CBOE $0.069 CIBC Qx U.S. Low Volatility Dividend ETF CQLU CBOE $0.032 CIBC Qx International Low Volatility Dividend ETF CQLI CBOE $0.056 CIBC 2025 Investment Grade Bond Fund — ETF Series CTBA CBOE $0.030 CIBC 2026 Investment Grade Bond Fund — ETF Series CTBB CBOE $0.029 CIBC 2027 Investment Grade Bond Fund — ETF Series CTBC CBOE $0.036 CIBC 2028 Investment Grade Bond Fund — ETF Series CTBD CBOE $0.035 CIBC 2029 Investment Grade Bond Fund — ETF Series CTBE CBOE $0.045 CIBC 2030 Investment Grade Bond Fund — ETF Series CTBF CBOE $0.038 CIBC 2025 U.S. Investment Grade Bond Fund — ETF Series (USD)* CTUC.U CBOE $0.018 CIBC 2026 U.S. Investment Grade Bond Fund — ETF Series (USD)* CTUD.U CBOE $0.024 CIBC 2027 U.S. Investment Grade Bond Fund — ETF Series (USD)* CTUE.U CBOE $0.027 CIBC Income Advantage Fund ETF CCLO CBOE $0.085 * Cash distribution per unit ($) amounts are USD for CUSD.U, CTUC.U, CTUD.U, and CTUE.U CIBC ETFs are managed by CIBC Asset Management Inc., a subsidiary of Canadian Imperial Bank of Commerce. Commissions, management fees and expenses all may be associated with investments in exchange traded funds (ETFs). Please read the CIBC ETFs prospectus or ETF Facts document before investing. To obtain a copy, call 1-888-888-3863, ask your advisor or visit ETFs are not guaranteed, their values change frequently, and past performance may not be repeated. CIBC ETFs are offered by registered dealers. Morningstar® Canada Core Bond Index™, Morningstar Canada 1-5 Year Core Bond Index and Morningstar® Global ex-Canada Core Bond Hedged CAD Index™, are trademarks or service marks of Morningstar, Inc., and have been licensed for use for certain purposes by CIBC Asset Management. CIBC Canadian Bond Index ETF, CIBC Canadian Short-Term Bond Index ETF and CIBC Global Bond ex-Canada Index ETF (CAD Hedged), are not sponsored, endorsed, sold or promoted by Morningstar, and Morningstar makes no representation regarding the advisability of investing in the CIBC Canadian Bond Index ETF, CIBC Canadian Short-Term Bond Index ETF and CIBC Global Bond ex-Canada Index ETF (CAD-Hedged). About CIBC CIBC is a leading North American financial institution with 14 million personal banking, business, public sector and institutional clients. Across Personal and Business Banking, Commercial Banking and Wealth Management, and Capital Markets, CIBC offers a full range of advice, solutions and services through its leading digital banking network, and locations across Canada, in the United States and around the world. Ongoing news releases and more information about CIBC can be found at About CIBC Asset Management CIBC Asset Management Inc. (CAM), the asset management subsidiary of CIBC, provides a range of high-quality investment management services and solutions to retail and institutional investors. CAM's offerings include: a comprehensive platform of mutual funds, strategic managed portfolio solutions, discretionary investment management services for high-net-worth individuals, and institutional portfolio management. CAM is one of Canada's largest asset management firms, with over $227 billion in assets under administration as of June 2025.
Malaysian Reserve
12 hours ago
- Malaysian Reserve
AAM to Announce Second Quarter Financial Results on August 8
DETROIT, July 25, 2025 /PRNewswire/ — American Axle & Manufacturing Holdings, Inc. (AAM), (NYSE: AXL) will hold a conference call to discuss second quarter financial results and other related matters at 10:00 a.m. ET on Friday, August 8, 2025. A press release announcing the results will be issued before the market opens on the same day and will be available at To participate by phone, please dial: (877) 883-0383 from the United States (412) 902-6506 from outside the United States Callers should reference access code 8504475. To participate by live audio webcast or listen to the briefing following the call, visit A replay will be available one hour after the call is complete until August 15, 2025. To listen to the replay please dial: (877) 344-7529 from the United States (412) 317-0088 from outside the United States When prompted, callers should enter replay access code 6368162. The audio replay will also be archived on AAM's website for one year. About AAMAs a leading global Tier 1 Automotive and Mobility Supplier, AAM designs, engineers and manufactures Driveline and Metal Forming technologies to support electric, hybrid and internal combustion vehicles. Headquartered in Detroit, MI, with over 75 facilities in 16 countries, AAM is bringing the future faster for a safer and more sustainable tomorrow. To learn more, visit For more information: Investor Contact Media Contact David H. Lim Christopher M. Son Head of Investor Relations Vice President, Marketing & Communications (313) 758-2006 (313) 758-4814 [email protected] [email protected]
Malaysian Reserve
12 hours ago
- Malaysian Reserve
IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation
Breast surgeon, Professor Eisuke Fukuma, a highly regarded cryoablation expert & ProSense® user at Kameda Medical Center, presented updated breast cancer cryoablation data from an independent study of over 600 women from 2006 to 2023 Independent ProSense® study by Professor Hisanori Kawamoto demonstrating 0% breast cancer local recurrence wins Best of Breast Cancer Award Leading US Breast Surgeon, Dr. Richard Fine, presented data from IceCure's ICE3 study & discussed other recent publications on breast cancer cryoablation CAESAREA, Israel, July 25, 2025 /PRNewswire/ — IceCure Medical Ltd. (Nasdaq: ICCM) ('IceCure', 'IceCure Medical' or the 'Company'), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced its participation in the 33rd Annual Meeting of the Japanese Breast Cancer Society's Conference (the 'Conference') which took place earlier this month in Tokyo. 'We believe ProSense® can make a significant impact on improving breast cancer outcomes in Japan by providing women with a minimally invasive option. This year's Conference was highly productive as we engaged with breast surgeons, thought leaders, and industry participants,' stated Eyal Shamir, IceCure's Chief Executive Officer. 'Working with Terumo Corporation in Japan, the country's largest medical device company, we anticipate strong commercial adoption upon regulatory approval for breast cancer, especially given the strong data coming from independent Japanese studies.' IceCure, a sponsor of the Conference, hosted a cryoablation-focused luncheon on Friday, July 11, 2025, led by Professor Takayuki Kinoshita, Division of Breast Surgery, NHO Tokyo Medical Center, with presentations made by: Professor Eisuke Fukuma, who has performed over 600 breast cryoablation procedures, the majority of which were conducted with ProSense®, presented the latest data from his ongoing activity to treat breast cancer at Kameda Medical Center. Professor Fukuma's presentation included the following: From June 2006 through December 2023, 535 breast cancer patients with tumor lesions of less than 15 millimeters and 76 patients with tumor lesions of less than 10 millimeters were treated. The overall ipsilateral breast tumor recurrence rate (IBTR') was 0.98% for up to 17 years, resulting in a 99.02% recurrence free rate. For a subpopulation with more than 10 years follow up, including 51 patients with invasive ductal carcinoma and 20 patients with ductal carcinoma in situ, the IBTR was 2.8%, resulting in a 97.2% recurrence free rate. From June 2006 through December 2023, 535 breast cancer patients with tumor lesions of less than 15 millimeters and 76 patients with tumor lesions of less than 10 millimeters were treated. The overall ipsilateral breast tumor recurrence rate (IBTR') was 0.98% for up to 17 years, resulting in a 99.02% recurrence free rate. For a subpopulation with more than 10 years follow up, including 51 patients with invasive ductal carcinoma and 20 patients with ductal carcinoma in situ, the IBTR was 2.8%, resulting in a 97.2% recurrence free rate. Dr. Richard Fine of West Cancer Center & Research Institute in the U.S., and a clinical investigator of IceCure's successfully completed ICE3 breast cancer clinical study, presented findings from the ICE3 study as well as data from independent studies of ProSense® in breast cancer. The Conference gave the Best of Breast Cancer award to an independent study published in the journal Breast Cancer titled 'Percutaneous ultrasound–guided cryoablation for early–stage primary breast cancer: a follow–up study in Japan'. This study was led by Professor Hisanori Kawamoto, M.D., Ph.D. from the Department of Breast Surgery, Breast and Imaging Center at St. Marianna University School of Medicine in Japan and reported zero (0%) breast cancer local recurrence 5 years following treatment with ProSense®. Dr. Kawamoto commented, 'This is a very important study in Japan, where we are experiencing an upward trend in breast cancer cases, especially among women in their late 40s to their early 60s. These are women who often are at very active stages of their life and therefore there is a growing demand for treatment options that minimize the chance of, or even avoid, hospitalization, in addition to resulting in favorable clinical and cosmetic outcomes. We are very pleased with these results and are hopeful that ProSense® may become a favored option in Japan upon regulatory approval for early-stage breast cancer.' Terumo Corporation is expected to submit an application to the Pharmaceuticals and Medical Devices Agency ('PMDA') of Japan for regulatory clearance for breast cancer indication for the ProSense® system by the end of 2025. About ProSense®The ProSense® Cryoablation System provides a minimally invasive treatment option to destroy tumors by freezing them. The system uniquely harnesses the power of liquid nitrogen to create large lethal zones for maximum efficacy in tumor destruction in benign and cancerous lesions, including breast, kidney, lung, and liver. ProSense® enhances patient and provider value by accelerating recovery, reducing pain, surgical risks, and complications. With its easy, transportable design and liquid nitrogen utilization, ProSense® opens that door to fast and convenient office-based procedures for breast tumors. About IceCure MedicalIceCure Medical (Nasdaq: ICCM) develops and markets advanced liquid-nitrogen-based cryoablation therapy systems for the destruction of tumors (benign and cancerous) by freezing, with the primary focus areas being breast, kidney, bone and lung cancer. Its minimally invasive technology is a safe and effective alternative to hospital surgical tumor removal that is easily performed in a relatively short procedure. The Company's flagship ProSense® system is marketed and sold worldwide for the indications cleared and approved to date including in the U.S., Europe and Asia. Forward Looking StatementsThis press release contains forward-looking statements within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as 'expects,' 'anticipates,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates' and similar expressions or variations of such words are intended to identify forward-looking statements. For example, IceCure is using forward looking statements in this press release when it discusses: the belief that ProSense® can make a significant impact on improving breast cancer outcomes in Japan; the Company's anticipation of strong commercial adoption upon regulatory approval of ProSense® for breast cancer; the belief of the importance of 'Percutaneous ultrasound–guided cryoablation for early–stage primary breast cancer: a follow–up study in Japan;' and that Terumo Corporation is expected to submit a PMDA application for regulatory clearance for breast cancer indication for the ProSense® system by the end of 2025. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Important factors that could cause actual results, developments and business decisions to differ materially from those anticipated in these forward-looking statements include, among others: the Company's planned level of revenues and capital expenditures; the Company's available cash and its ability to obtain additional funding; the Company's ability to market and sell its products; legal and regulatory developments in the United States and other countries; the Company's ability to maintain its relationships with suppliers, distributors and other partners; the Company's ability to maintain or protect the validity of its patents and other intellectual property; the Company's ability to expose and educate medical professionals about its products; political, economic and military instability in the Middle East, specifically in Israel; as well as those factors set forth in the Risk Factors section of the Company's Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC on March 27, 2025, and other documents filed with or furnished to the SEC which are available on the SEC's website, The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law. References and links to websites have been provided in this press release as a convenience, and the information contained on such websites is not incorporated by reference herein. IR Contact: Email: investors@ Michael Polyviou Phone: 732-232-6914 Logo – View original content:
